Cyclarity Therapeutics, a clinical stage biopharmaceutical company co-founded by Dr. Amelia Anderson, Matthew O’Connor and Michael Kope, presented research at the American Heart Association Vascular Discovery Scientific Sessions 2026 that could mark a pivotal milestone toward moving heart disease treatments from managing arterial damage to reversing its course. The research marks the first clinical evidence that 7-ketocholesterol (7KC), the root cause of atherosclerosis, can be safely targeted and removed from the human body.
Cyclarity Therapeutics, a clinical stage biopharmaceutical company co-founded by Dr. Amelia Anderson, Matthew O’Connor and Michael Kope, presented research at the American Heart Association Vascular Discovery Scientific Sessions 2026 that could mark a pivotal milestone toward moving heart disease treatments from managing arterial damage to reversing its course. The research marks the first clinical evidence that 7-ketocholesterol (7KC), the root cause of atherosclerosis, can be safely targeted and removed from the human body.